Bellicum

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally.

Morgan Prestwich were retained under a Master Service Agreement (MSA) to build Bellicum's entire European operation:
- President International
- Above country Commercial (Market Access, Marketing, Government Affairs)
- Above country Medical
- GM's across Germany, UK, France, Italy and Spain
- Medical Directors Germany, UK, France, Italy and Spain
- In-Country Market Access Germany, UK, France, Italy and Spain

Project came to an end due to trial concerns and a pullback from international operations.